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Abstract  
Objective To characterise the cardiopulmonary characteristics of two different anaesthetic 
protocols (tiletamine/zolazepam +/- medetomidine) and their suitability for the 
immobilisation of healthy chimpanzees undergoing cardiac assessment. 
Study design Prospective, clinical, longitudinal study 
Animals Six chimpanzees (Pan troglodytes) aged 4 - 16 years weighing 19.5 - 78.5 kg were 
anaesthetized on two occasions  
Methods Anaesthesia was induced with tiletamine/zolazepam (TZ) (3-4 mg kg-1) or 
tiletamine/zolazepam (2 mg kg-1) and medetomidine (0.02 mg kg-1) (TZM) via blow dart 
(IM) and maintained with intermittent boluses of ketamine (IV) or zolazepam/tiletamine (IM) 
as required. The overall quality of the anaesthesia was quantified based on scores given for: 
quality of induction, degree of muscle relaxation and ease of intubation.  The time to achieve 
a light plane of anaesthesia, number of supplemental boluses needed and recovery 
characteristics were also recorded. Chimpanzees were continuously monitored and heart rate 
(HR), pulse rate (PR), respiratory rate (fR) oxygen saturation of heamoglobin (SpO2), systolic 
arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), 
rectal temperature, mucous membrane colour and capillary refill time recorded. During the 
first procedure (TZ) animals underwent a 12 channel ECG, hematology, biochemistry and 
cardiac biomarker assessment to rule out the presence of pre-existing cardiovascular disease. 
A detailed echocardiographic examination was carried out by the same blinded observer 
during both procedures. Data were compared using Student’s paired t-test or Wilcoxon rank 
tests as appropriate.  
 
Results There was a significant difference for the area under the curves between anaesthetic 
protocols for HR, SAP, MAP and fR. No significant differences in the echocardiographic 
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measurements were evident. Quality of anaesthesia was significantly better with TZM and no 
additional boluses were required. The TZ protocol required multiple supplemental boluses.  
Conclusions and clinical relevance Both combinations are suitable for immobilization and 
cardiovascular evaluation of healthy chimpanzees. Further work is required to evaluate the 
effect of medetomidine in cardiovascular disease. 
 
Keywords  chimpanzee, Pan troglodytes, medetomidine, ketamine, tiletamine-zolazepam 
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Introduction 
The topic of cardiovascular disease among chimpanzee (Pan troglodytes), gorilla (Gorilla 
gorilla gorilla), orangutans (Pongo pygmaeus) and bonobos (Pan paniscus) has featured 
heavily in the zoological literature in recent years (Strong et al. 2016) being identified as a 
major cause of mortality across all the great ape taxa. Affected animals often do not display 
clinical signs, presenting only as cases of sudden death (Lammey et al. 2008). For this reason, 
pro-active screening is key to identifying affected animals early in the disease process, but 
the size and dangerous nature of the animals necessitates that cardiac assessments are usually 
performed under anaesthesia (Cerveny & Sleeman 2014). A small number of (mostly 
American) zoos are undertaking conscious echocardiographic evaluation in trained animals, 
but the restrictions of scanning an animal, through mesh or bars for safety, severely restricts 
the probe angles and positions and thus the diagnostic potential.  
The alpha-2-agonist medetomidine, is frequently incorporated with ketamine or 
tiletamine/zolazepam, because it contributes to rapid safe induction; stable, and reversible 
immobilization, excellent muscle relaxation and smooth recoveries. Medetomidine binds to 
alpha-adrenergic receptors in the peripheral vasculature, causing vasoconstriction and an 
increased systemic vascular resistance. The initial effect is an increase in blood pressure, but 
the baroreceptor response typically causes slowing of the heart and a reduced cardiac output 
(Khan et al. 1999). In great apes, medetomidine use remains controversial given anecdotal 
reports that it impedes meaningful echocardiographic interpretation and, may contribute to 
increased perioperative mortality in those animals with pre-existing heart disease (Brainard 
2016).  
The aim of this study was to compare the effects of two different anaesthetic protocols 
(tiletamine/zolazepam +/- medetomidine) and evaluate their suitability for the immobilisation 
of healthy chimpanzees undergoing cardiac assessment. 
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Materials and methods 
This work was carried out at Kolmården Wildlife Park, Sweden. Ethical approval was 
granted by the University of Nottingham’s ethics committee (1692 160222). 
 
Animals 
Six chimpanzees, two males and four females from a mixed age group (n=25) were studied. 
They were housed in an indoor/outdoor enclosure with free access to drinking water, a mixed 
diet of vegetables, fruit, branches and pellets. The animals were being moved to another 
collection and required two anaesthetics, one for pre-export health assessment and one for 
transport on the day of export. 
The study was carried out as a prospective, clinical, longitudinal study.  Food, but not water, 
was withheld for > 6 hours prior anaesthesia.   
 
Induction of anaesthesia 
For the first procedure estimated body weights were used and all chimpanzees were offered 
midazolam orally followed by IM tiletamine-zolazepam 3-4 mg kg-1 (Zoletil 100 Vet; Virbac, 
France;) (TZ). For the second procedure, 8 weeks later, a combination of IM tiletamine-
zolazepam (2 mg kg-1) and medetomidine (0.02 mg kg-1) (Zalopine; Orion Pharma, Finland) 
(TZM) was used (without oral midazolam). The animals’ pre-darting (post-midazolam for TZ 
individuals that did accept midazolam) activity level and demeanour at induction were scored 
(ranging from 1 to 4 Appendix A) using a basic descriptive scale. The time taken to achieve a 
light plane of anaesthesia (defined as recumbency, muscle relaxation, and absence of 
voluntary movements) after darting was recorded in minutes.  
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Maintenance of anaesthesia 
After induction of anaesthesia, animals were weighed and oxygen was delivered via an 
endotracheal tube (Teleflex Medical, Ireland), or if tracheal intubation was difficult via nasal 
tube (Mediplast AB, Sweden). Supplemental doses of ketamine (Ketaminol vet; Intervet, The 
Netherlands) +/- tiletamine-zolazepam were administered IM/IV as required (Table 1). 
 
Monitoring of anaesthesia 
Continuous monitoring commenced once the animals were on the examination table and the 
following parameters were recorded at 5-minute intervals: respiratory rate (fR), eye position, 
palpebral reflex, jaw tone, muscle relaxation, spontaneous movement, heart rate (HR) (via 
auscultation) and pulse rate (PR) (via palpation of the femoral artery). Arterial oxygen 
saturation (SpO2%) was measured using a pulse oximeter (WM 2160; Viamed Ltd, UK) with 
the probe placed on the lip/tongue. Blood pressures were measured using a non-invasive 
oscillometric device (BMG 4907; AEG, Germany) with a cuff width approximately 40% of 
the circumference, placed on the arm. An echocardiographic examination (Vivid q ultrasound 
system; GE Healthcare, UK) was performed as per guidelines issued for European zoos 
(available from: https://twycrosszoo.org/wp-content/uploads/2018/05/C2-Standardised-echo-
protocol.pdf with the following echocardiographic measurements collected: left atrial 
diameter (LA), aortic root diameter (Ao), interventricular septum thickness in diastole 
(IVSd), left ventricular end diastolic diameter (LVIDd), left ventricular end systolic diameter 
(LVIDs), left ventricular posterior wall thickness (LVPW), ejection fraction (EF; by 
Simpson’s biplane), left ventricular outflow tract diameter (LVOT), peak flow velocity at the 
pulmonic valve (VelPV) and aortic valve (VelAV), tissue (E and A wave) velocities (E’ vel., A’ 
vel.). Routine health assessment was performed during both procedures including 
haematology and biochemistry. During TZ, a 12-channel electrocardiogram (CardioExpress 
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SL6, Spacelabs Healthcare Ltd., United Kingdom); blood sampling for serum cardiac 
biomarkers and serological screening and comparative intra-palpebral tuberculin testing was 
undertaken. Additional medical/surgical interventions were also carried out as required for 
each animal. 
The overall quality of the anaesthetic was quantified based upon the combined scores for: 
quality of induction (1: excellent to 4: poor); degree of muscle relaxation (1: excellent to 4: 
poor) and; ease of intubation (1: easy to 4: extremely difficult). The plane of anaesthesia and 
any supplemental doses was also scored. Descriptions of all scoring criteria used are provided 
in Appendix A. 
At the end of the procedure, animals were moved to their enclosure (TZ) or transport crate 
(TZM). The medetomidine was antagonised by IM administration of atipamezole (Antisedan 
vet; Orion Pharma Animal Health, Sweden) at five times the dose of the medetomidine. All 
animals were positioned in lateral recumbency, administered oxygen and monitored closely 
throughout recovery.  
 
Statistical Analyses 
Statistical tests were performed using GraphPrism 7 (GraphPad Software; CA, USA). The 
normality assumptions were tested with Shapiro-Wilk test. Parametric data were compared 
using paired Students t-tests, with Wilcoxon matched pairs test for non-parametric data. Data 
are presented as mean (± SD) or median (range). Differences were considered statistically 
significant when p < 0.05.  
 
Results 
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Preanaesthetic aggression and high activity levels (scores 3 - 4) were common for both 
procedures. All animals were found to be in good overall health. Cardiac auscultation, ECG 
and cardiac biomarker results were within normal ranges. 
 
Induction and Maintenance of anaesthesia 
For the first procedure two of the animals took the complete midazolam dose offered, two 
animals took 80% and 90% respectively and two chimps refused the dose completely.  Oral 
midazolam was not offered for the second procedure. There was no significant difference in 
the time taken to achieve a light plane of anaesthesia between the two protocols, however, the 
quality of anaesthetic induction was significantly better for TZM (p = 0.0312). For TZ, the 
plane of anaesthesia achieved was scored as being light, whereas for TZM it was rated as 
surgical. The median number of supplemental doses required during the TZ procedure was 
3.5 (2-7); no additional anaesthetic agents were administered during TZM. For one induction 
(Chimpanzee 2, procedure 1) the dart did not fully discharge. This animal required two 
further doses of ketamine (105 mg). 
 
Cardiopulmonary parameters 
The time to echocardiographic examination from induction of anaesthesia was 40 (23-75) 
minutes and was not significantly different between groups (p = 0.05).  
Data relating to all haemodynamic and respiratory parameters for both anaesthetic protocols 
are displayed in Table 1. Data were compared (AUC) between protocols over the time course 
of the anaesthetic. The area under the curve for SAP, MAP, HR, and fR for the TZM 
anaesthetic protocol was significantly different to the TZ protocol. TZM was associated with 
significantly lower heart and pulse rates as well as lower systolic and mean arterial blood 
pressure when compared with the TZ protocol. One period of hypotension (defined as MAP 
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below 70 mmHg) occurred in one chimp (Chimp 3) during TZM lasting 15 minutes with a 
nadir of 48 mmHg. Blood pressure measurements obtained with TZ exceeded normal 
published ranges (Erickson & Olsen 1985). Arterial oxygen saturation was lower for TZM 
compared to TZ.  
 
Echocardiography 
None of the differences in echocardiographic measurements between the two protocols were 
statistically significant.  
 
Duration  
Anaesthetic duration for TZ (75 ± 13 minutes) was not significantly longer than TZM (64 ± 
14 minutes).  
 
Anaesthetic recovery 
Following TZ, five of the six recoveries were rated as excellent (score 1 out of 4) and one 
rated as poor (score 3 out of 4). All TZM recovery scores were rated as excellent (score 1 out 
of 4).  
 
 
 
Discussion 
TZM was associated with a significantly lower heart rate and mean arterial blood pressure 
when compared to TZ. Bradycardia and hypotension are well recognised effects of 
medetomidine in other species. In healthy animals these changes are generally no cause for 
concern and, in fact, the comparatively higher blood pressures observed following TZ are 
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more concerning and potentially detrimental (Wongprasartsuk & Sear 2003). They reflect an 
increase in sympathetic drive/tone; which is a feature of dissociative anaesthesia but might 
also be expected due to the comparatively lighter plane of anaesthesia. Such increased 
sympathetic drive has the potential to increase myocardial oxygen demand and increase the 
risk of cardiac arrhythmias. In contrast, alpha-2-agonists prevent catecholamine-induced 
arrhythmias (Hayashi et al. 1991). Given that chimpanzee cardiac deaths have been attributed 
to terminal arrhythmias (Lammey 2008) these factors should be considered.  
 
Echocardiography parameters 
In this study, medetomidine in combination with tiletamine/zolazepam was not associated 
with a significant decrease in cardiac output and function. Echocardiographic parameters for 
TZM anaesthesia in this study were similar to the those for adult chimpanzees during 
tiletamine-zolazepam anaesthesia in another study (Sleeper et al. 2014). Specifically, these 
findings therefore contradict the conclusion drawn by Napier et al. (2013), who compared 
echocardiographic and blood pressure measurements of seven gorillas during three stages of 
an anaesthetic protocol and concluded medetomidine caused a significant reduction in 
ejection fraction and increased left ventricular dimension, thereby recommending caution. 
Notwithstanding this conclusion, five of the seven gorillas did have evidence of 
cardiovascular disease and given that the diseased heart is likely to respond differently to 
anaesthesia compared to a healthy heart these findings may not be widely representative and 
might explain the differences in conclusions drawn by this and our study. Differences might 
also be attributable to a different study population (gorillas versus chimpanzees), study 
design (ketamine and medetomidine) drug dose range (medetomidine 0.05 – 0.07 mg kg-1) in 
an all-male group (Napier et al. 2013). 
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Anaesthetic quality  
TZM produced a smoother induction and improved muscle relaxation, easier endotracheal 
intubation and a surgical plane of anaesthesia without supplemental drug administration. 
Particularly when working with dangerous animals, the anaesthetic plane is an important 
clinical and safety consideration. With TZ, the chimpanzees exhibited a greater degree of 
muscle tension and reflex activity prolonging some of the diagnostics.  A clinician unfamiliar 
with TZ anaesthesia might conclude the animal is inadequately anaesthetised and administer 
unnecessary supplemental doses. Following this study, it was the opinion of the authors that 
TZ resulted in the immobilization of an animal, suitable for example: for moving it into 
another enclosure or hospital facility or; in the hands of a confident/experienced anaesthetist, 
a non-invasive health assessment, but not a surgical plane of anaesthesia. 
From the echocardiographer’s perspective adequate muscle relaxation also aids image 
acquisition, and this was subjectively reported to be easier during TZM anaesthesia. 
 
 
 
 
Clinical implications  
Whilst several great apes housed in North American zoos have been trained for conscious 
echocardiographic and/or blood pressure assessment, this is not commonplace and views 
obtained even in a well-trained animal are still often of limited diagnostic quality.  
The Great Ape Heart Project (GAHP; based at Zoo Atlanta, USA) recommend that great apes 
of unknown cardiovascular disease status and those undergoing cardiac assessment should 
not be anaesthetised using alpha-2-agonists based on the concern these drugs impede 
meaningful interpretation of echocardiographic assessment and may be associated with an 
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increased risk of mortality. This study provides insufficient evidence of such effects to 
substantiate such advice and therefore no advice relating to the use of specific drugs for great 
apes undergoing routine cardiac assessment is currently issued by the European vet advisors.  
 
Limitations of the study  
The clinical nature of this study meant that there were several variables that could not be 
controlled. Firstly, induction agents were administered based upon estimated rather than 
actual bodyweights but good accuracy (mean 5% over/under-estimation) meant this effect 
was likely minimal. It was also not possible to control the need for additional boli and total 
drug doses.  Furthermore, data recording did not start immediately after drug administration; 
and there is a possibility of changes such as the initial hypertension following TZM was 
missed. Although oral midazolam was offered prior to TZ it was taken with variable success, 
and not offered prior to TZM in view of the poor uptake and limited effects. Oral midazolam 
has been shown to induce sedation and anxiolysis in humans although a recent Cochrane 
review found no high-quality evidence to suggest midazolam was more or less effective than 
placebo or other medications (Conway et al. 2016). Training animals to accept hand injection 
rather than being darted can significantly reduce stress at the time of induction of anaesthesia. 
 
Conclusions  
Both TZ and TZM combinations are suitable for immobilization and cardiovascular 
evaluation of healthy chimpanzees, although TZM offers additional benefits. Further work is 
required to evaluate the effects of medetomidine in animals with cardiovascular disease. 
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Characteristic Score Description 
Pre-anaesthetic 
activity level 
1 None; very still  
2 Low; small amount of activity, e.g. moving to elsewhere in enclosure to avoid aim of dart gun 
3 Moderate; moving around enclosure to numerous locations prior to the successful administration of the induction agent 
4 High; constant moving around enclosure to numerous locations, resulting in significant prolongation of the time required to administer induction agent   
Pre-anaesthetic 
demeanour 
1 Depressed; collapsed, reduced or lack of awareness of external stimuli, e.g. sick or sedated animal  
2 Alert; aware of stimuli but reduced response compared with anticipated level of response, relaxed 
3 Apprehensive; responsive to stimuli, taking avoiding action e.g. hiding in corner of enclosure or behind another individual   
4 Aggressive; hyper-responsive to stimuli, displaying violent activity e.g. to the veterinarian administering induction agent  
Quality of 
induction 
1 Excellent; rapid, calm and smooth induction, recumbency and adequate and safe level of anaesthesia achieved 
2 
Good; slightly prolonged but smooth induction, recumbency and adequate and safe level of anaesthesia 
achieved but some movement/response to stimulus remains e.g. able to be safely moved from enclosure 
but requires additional anaesthesia for intubation 
3 Fair; recumbency but not adequate/safe level of anaesthesia achieved, still has sluggish responses to stimuli and requires additional anaesthetic agents to be administered before can be safely handled  
4 Poor; inadequate sedative effect achieved, very responsive to stimuli, requires administration of additional anaesthetic agents before observers can enter enclosure 
Degree of 
muscle 
relaxation 
1 Excellent; trunk and limb muscle relaxed, no muscle tone or twitching 
2 Good; muscles relaxed, occasional mild muscle twitching in small focal regions of body, e.g. eyes, lips, hands, feet  
3 Fair; small amount of muscle tone, sustained or repeated muscle twitching of larger muscle bodies, e.g. whole limb movement 
4 Poor; muscles rigid, severe muscle twitching of multiple large muscle groups e.g. trunk and/or limbs   
Depth of 
anaesthesia 
1 Mild sedation; slight sedation, still able to move around without ataxia but at slower speed than usual 
2 Heavy sedation; responds to stimuli e.g. sound/touch with purposeful movements, safe level of anaesthesia for handling of e.g. non-dangerous animals  
3 Light anaesthesia; safe level of anaesthesia for handling dangerous animals, non-responsive to stimuli e.g. sound/touch, responsive to painful stimuli, most reflexes still present  
4 Surgical anaesthesia; non-responsive to painful stimuli, appropriate level of anaesthesia for e.g. surgical intervention, most reflexes are absent 
5 Excessively deep anaesthesia; excessive depression of central nervous system results in reduced ability to maintain normal functions e.g. respiration, animal at risk of anaesthetic death 
Ease of 
intubation 
1 Easy; coughing/gagging absent or minimal  
2 Moderate; small to moderate amount of reflex coughing/gagging but intubation achieved without need for additional (top-up) anaesthesia 
3 Difficult; pronounced coughing, intubation requires additional anaesthetic agents to be administered   
4 Extremely difficult; severe swallowing, coughing or gagging, intubation requires additional anaesthetic agents to be administered or is unsuccessful   
Anaesthetic 
recovery 
1 Excellent; smooth, non-vocal without paddling or uncoordinated movement 
2 Good; some minor paddling/excitation of short duration but no vocalisation or uncoordinated movement 
3 Fair; some vocalisation, paddling or uncoordinated movement but of short duration and easily calmed  
4 Poor; vocalisation, paddling or uncoordinated movement of moderate to severe duration and intensity  
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10
0±
11
 
59
±5
 
79
±3
 
64
±3
 
90
±3
 
79
±8
 
80
±8
 
68
±9
 
87
±3
 
62
±6
* 
SA
P (
mm
Hg
) 
17
1±
15
 
13
6±
24
 
12
1±
19
 
12
1±
22
 
- 
98
±1
6 
14
1±
25
 
10
6±
18
 
15
5±
24
 
13
4±
12
 
- 
10
9±
19
 
15
0±
23
 
11
6±
22
* 
DA
P (
mm
Hg
) 
10
4±
15
 
79
±1
6 
91
±1
9 
78
±1
4 
- 
55
±1
5 
86
±2
 
74
±5
 
82
±9
 
69
±4
 
- 
64
±1
2 
92
±1
5 
69
±1
5 
M
AP
 (m
mH
g) 
12
8±
14
 
98
±1
0 
10
1±
16
 
91
±5
 
- 
69
±1
5 
10
4±
3 
85
±3
 
10
6±
6 
91
±4
 
- 
79
±1
3 
11
1±
10
 
85
±1
1*
* 
Sp
O 2
 (%
) 
98
±3
 
- 
98
±2
 
96
±5
 
- 
97
±6
 
98
±1
 
93
±4
 
97
±1
 
89
±5
 
- 
- 
98
±1
 
93
±4
**
**
 
f R 
(br
ea
ths
 m
inu
te-
1 ) 
15
 
13
 
13
 
15
 
23
 
13
 
17
 
18
 
17
 
16
 
29
 
26
 
20
 
16
* 
MA
NU
SC
RIP
T
 
AC
CE
PT
ED
A
C
C
EP
TE
D
 M
A
N
U
SC
R
IP
T
 1 D
ura
tio
n o
f a
na
est
he
sia
: f
rom
 ad
mi
nis
tra
tio
n o
f i
nd
uc
tio
n a
ge
nt 
to 
sp
on
tan
eo
us
 w
ak
ing
 (T
Z)
 or
 re
ve
rsa
l (
TZ
M
) w
as 
pu
rpo
sef
ull
y m
an
ipu
lat
ed
 fo
r 
log
ist
ic/
saf
ety
 re
aso
ns
 
2 S
up
ple
me
nta
l b
olu
ses
 of
 ke
tam
ine
 (K
) o
r t
ile
tam
ine
-zo
laz
ep
am
 (T
Z)
 or
 bo
th 
we
re 
ad
mi
nis
ter
ed
 at
 th
e d
isc
ret
ion
 of
 th
e s
am
e a
na
est
he
tis
t to
 im
pro
ve
 th
e p
lan
e 
of 
an
ae
sth
esi
a. 
HR
, f R
, N
IB
P a
nd
 Sp
O 2
 ar
e g
ive
n a
s m
ea
n ±
 SD
, w
ith
 ag
e g
ive
n a
s m
ed
ian
 (r
an
ge
) a
nd
 th
ese
 w
ere
 ca
lcu
lat
ed
 fr
om
 al
l m
ea
su
rem
en
ts 
tak
en
 du
rin
g a
na
est
he
sia
.  
 HR
, h
ea
rt 
rat
e; 
f R,
 re
sp
ira
tor
y r
ate
; S
AP
, s
ys
tol
ic 
art
eri
al 
pre
ssu
re;
 D
AP
, d
ias
tol
ic 
art
eri
al 
pre
ssu
re;
 M
AP
, m
ea
n a
rte
ria
l p
res
su
re;
  S
pO
2, o
xy
ge
n s
atu
rat
ion
 of
 
ha
em
og
lob
in;
 A
o, 
ao
rti
c r
oo
t d
iam
ete
r; 
LA
, le
ft 
atr
ial
 di
am
ete
r; 
IV
Sd
, in
ter
ve
ntr
icu
lar
 se
ptu
m 
thi
ck
ne
ss 
in 
dia
sto
le;
 L
VI
Dd
 le
ft 
ve
ntr
icu
lar
 en
d d
ias
tol
ic 
dia
me
ter
; L
VI
Ds
, le
ft 
ve
ntr
icu
lar
 en
d s
ys
tol
ic 
dia
me
ter
; L
VP
W
, le
ft 
ve
ntr
icu
lar
 po
ste
rio
r w
all
 th
ick
ne
ss;
 E
F, 
eje
cti
on
 fr
ac
tio
n. 
  * p
 ≤ 
0.0
5*
* p
 ≤ 
0.0
1;
 **
**
 p 
≤ 0
.00
01
 de
no
tes
 st
ati
sti
ca
l d
iff
er
en
ce
s b
etw
ee
n t
he
 ar
ea
 un
de
r t
he
 cu
rv
es
 of
 T
Z 
an
d T
ZM
 gr
ou
ps
 
A O
 (m
m)
 
21
 
23
 
20
 
22
 
17
 
17
 
22
 
27
 
22
 
22
 
17
 
18
 
20
 
22
 
LA
 (m
m)
 
35
 
37
 
33
 
25
 
23
 
23
 
37
 
35
 
30
 
35
 
22
 
25
 
30
 
30
 
IV
Sd
 (m
m)
 
9 
11
 
8 
8 
- 
6 
9 
10
 
8 
11
 
7 
- 
8 
9 
LV
ID
d (
mm
) 
49
 
48
 
41
 
42
 
- 
31
 
46
 
44
 
42
 
38
 
40
 
- 
44
 
41
 
LV
ID
s (
mm
) 
28
 
30
 
29
 
29
 
- 
20
 
29
 
30
 
26
 
25
 
26
 
- 
28
 
27
 
LV
PW
 (m
m)
 
8 
10
 
7 
6 
- 
6 
9 
9 
8 
6 
6 
- 
8 
6 
EF
 (%
) 
55
 
55
 
60
 
50
 
50
 
64
 
55
 
- 
58
 
55
 
60
 
54
 
56
 
56
 
